nach oben

Annals of Hematology

Erschienen in:

01.04.2005 | Review Article

Recent developments in the management of invasive fungal infections in patients with hematological malignancies

verfasst von: Meinolf Karthaus, Oliver A. Cornely

Erschienen in: Annals of Hematology | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Despite recent advances in the last decade, invasive fungal infections are still associated with a high morbidity and mortality. Invasive fungal infections constitute severe infectious complications in patients with hematological malignancies receiving myelosuppressive chemotherapy or sustained immunosuppression after allogeneic transplant regimens. Following a long period of stagnation, considerable progress has been made during the last 5 years in non-culture-based diagnostics and in the treatment of invasive fungal infections. This review highlights recent developments in the epidemiology, diagnosis, and treatment in the context of state-of-the-art management of invasive fungal infections in cancer patients.

Almyroudis N, Jaffe D, Sepkowitz KA, Pamer EG, Meier EN, Papadopoulos E, Small TN, Papanicolaou GA (2003) Risk factors for late invasive aspergillosis (IA) after allogeneic stem cell transplantation. In: 43rd ICAAC abstracts, American Society for Microbiology, September 2003, p 457, M-1006

Ascioglu S, Rex JH, de Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14CrossRefPubMed

Bischoff TR, Tallent S, Adera T, Wenzel RP, Edmond MB (2003) Epidemiology of nosocomial candidemia: a six-year national perspective. In: 43rd ICAAC abstracts, American Society for Microbiology, September 2003, p 348, K 452e

Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135:412–422

Bow EJ, Laverdière M, Lussier N, Rotstein C, Cheang MS, Ioannou S (2002) Antifungal prophylaxis for severely neutropenic chemotherapy recipients. A meta-analysis of randomized-controlled clinical trials. Cancer 94:3230–3246

Buchheidt D, Hummel M, Schleiermacher D, Spiess B, Skladny H, Schwerdtfeger R, Cornely OA, Wilhelm S, Reuter S, Kern WV, Suedhoff T, Moerz H, Hehlmann R, German Aspergillus PCR Study Group. Prospective multicenter clinical evaluation of a nested PCR assay, a lightcycler mediated PCR assay and a galactomannan ELISA for detection of invasive aspergillosis in neutropenic high risk patients. In: 43rd ICAAC Abstracts, American Society for Microbiology, September 2003, p 478, M-2057

Buechner T, Fegeler W, Berhardt H et al (2002) Treatment of severe candida infections in high-risk patients: an interdisciplinary consensus. Eur J Clin Microbiol Infect Dis 21:337–352

Cornely OA, Ullmann AJ, Karthaus M (2003) Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 101:3365–3372

Cornely OA, Bethe U, Böhme A Buchheidt D, Cesaro S, Karthaus M, Maertens J et al (2003) Detection of predictor variables for breakthrough invasive fungal infection (IFI) during secondary prophylaxis (SP). Results from a European registry. In: 43rd ICAAC Abstracts, American Society for Microbiology, September 2003, p 456, M-1001

10.

Denning DW, Ribaud P, Milpied N et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571CrossRefPubMed

11.

Edwards JE Jr, Bodey GP, Bowden RA et al (1997) International conference for the development of a consensus on the management and prevention of severe candidal infections [see comments]. Clin Infect Dis 25:43–59

12.

Eser B, Yildiz O, Altuntas F, Alp E, Sari I, Ozkan M, Ekici E, Koc N, Cetin M, Ilhan O, Unal A (2003) Microbiologically documented bacterial and fungal infections following peripheral blood stem cell transplantation for hematological malignancies (abstract 5514). In: Proceedings 45th ASH 2003

13.

Greenberg RN, Anstead G, Herbrecht R, Langston A, Marr K, Mullane K, Raad I, Schiller G, Schuster M, Van Burik J, Wingard JR, Hare R, Corcoran G (2003) Posaconazole (POS) experience in the treatment of zygomycosis. In: 43rd ICAAC abstracts, American Society for Microbiology, September 2003, p 476, M-1757

14.

Harousseau JL, Locatelli F, Perez A, Ramirez PD, Michallet M (2003) Amphotericin B lipid complex (ABLC) for prophylaxis of fungal infections in patients given either unrelated or mismatched related donor (abstract 3624). In: Proceedings 45th ASH 2003

15.

Hebart H, Löffler J, Reitze H, Engel A, Schumacher U, Klingebiel T et al (2000) Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections. Implications for the management of febrile neutropenia. Br J Haematol 111:635–640

16.

Hebart H, Loeffler J, Kanz L, Einsele H (2000) Molecular methods in the diagnosis of infections in the immunocompromised host. Curr Opin Infect Dis 13:355–359

17.

Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415CrossRefPubMed

18.

Herbrecht R (2003) Early diagnosis: CT, antigen, or PCR (abstract 1328)? In: 43rd ICAAC abstracts, American Society for Microbiology, September 2003, p 524

19.

Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751CrossRefPubMed

20.

Jarvis WR (1995) Epidemiology of nosocomial infections, with emphasis on Candida species. Clin Infect Dis 20:1526–1530PubMed

21.

Karthaus M, Ullmann AJ, Cornely OA (2004) Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med 140:579–580

22.

Kullberg BJ, Pappas P, Ruhnke M, Viscoli C, Cleary JD, Church LWP, Brown JM, Rex JH, Hilton F, Oborska I, Hodges M, Schlamm H, Sobel J (2004) Voriconazole compared with a strategy of amphotericin B followed by fluconazole for treatment of candidaemia in non-neutropenic patients(abstract). ECCMID 2004:0245

23.

Maertens J, Raad I, Petrikkos G, Selleslag D, Petersen FB, Sable CA, Kartsonis N, Ngai A, Taylor A, Patterson TF, Denning D, Walsh TJ (2002) Update of the multicenter, noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents: an analysis of 90 patients. In: 42nd Interscience conference on antimicrobial agents and chemotherapy

24.

Maertens JA, Theunissen K, Verbeken E, Katrien L, Verhaegen J, Boogaerts M, Van Eldere J (2004) Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and hematological stem cell recipients. Br J Haematol 126:852-860

25.

Maertens J, Raad I, Sable CA, Ngai A, Berman R, Patterson TF, Denning D, Walsh T. Multicenter (2000) Noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to amphotericin B (AMB), AMB lipid formulations (lipid AMB), or azoles. In: 40th ICAAC, Toronto, 2000, Abstract 1103:371

26.

Marr KA, Carter RA, Boeckh M, Martin P, Corey L (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100:4358–4366

27.

Marr K, Hachem R, Papanicolaou G, Somani J, Arduino JM, Lipka J, Ngai A, Chodakewitz J, Sable C (introduction by Michael Boeckh). Retrospective study of concomitant use of caspofungin with cyclosporin A (CsA) in patients treated during marketed use (abstract 3613). In: Proceedings 45th ASH 2003

28.

Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103:1527–1533

29.

Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, McDonald GB (2004) Cyclophosphamide metabolism is affected by azole antifungals. Blood 103:1557–1559

30.

Marty FM, Cosimi LA, Baden LR (2004) Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350:950–952CrossRef

31.

Mattei D, Mordini N, Lo Nigro C, Musso M, Gallamini A (2003) Galactomannan antigenemia for early diagnosis and treatment of invasive aspergillosis: three years single centre experience (abstract 3632). In: Proceedings 45th ASH 2003

32.

Mattiuzzi GN, Kantarjian H, Alvarado G, Kontoyiannis D, Pierce S, Cortes J, Giles F, Raad I, Verstovsek S, Leitz G, Estey E (2003) Intravenous itraconazole (ITRA) vs caspofungin (CASPO) prophylaxis (P) in patients (PTS) with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC). In: 43rd ICAAC abstracts, American Society for Microbiology, September 2003, p 451, M-984

33.

Mora-Duarte J, Betts R, Rotstein C, Lopes-Colombo A, Thomson-Moya L, Smietana J et al (2002) Caspofungin (CAS) versus Amphotericin B deoxycholate (AmB) in the treatment (Rx) of invasive candidiasis (IC) in neutropenic (N) and non-neutropenic (NN) patients (Pts): a multicentre, randomized, double-blind study. N Engl J Med 347:2020–2029CrossRefPubMed

34.

Morrissey C.O., Halliday C., Chen S., Slavin M., Wesselingh S., Sorrell T. Comparison of the Sensitivity and Specificity of Aspergillus galactomannan (GM) sandwich ELISA and a nested Aspergillus PCR assay for the diagnosis of invasive aspergillosis (IA). In: 43rd ICAAC abstracts, American Society for Microbiology, September 2003, p 460, M-1019

35.

Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, Voltarelli JC, Colombo AL, Imhof A, Pasquini R, Maiolino A, Souza CA, Anaissie E (2004) Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 38:1237–1242

36.

Pappas PG, Morgan J, Hajjeh RA, Transplant Associated Infection Surveillance Network (TRANSNET) (2003) Prospective surveillance for invasive fungal infections (IFIs) in hematopoietic stem cell (HSCTs) and solid organ transplant recipients (SOTs) in the United States. In: 43rd ICAAC abstracts, American Society for Microbiology, September 2003, p 458, M-1010

37.

Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE (2004) Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 38:161–189CrossRefPubMed

38.

Patterson TF, Kirkpatrick WR, White M et al (2000) Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79:250–260

39.

Redding SW, Kirkpatrick WR, Coco BJ, White WS, Patterson TF, Marr KA (2003) Oral colonization as a source of Candida glabrata candidemia with allogeneic bone marrow transplant. In: 43rd ICAAC abstracts, American Society for Microbiology, September 2003, p 458, M-1011

40.

Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP et al (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331:1325–1330CrossRefPubMed

41.

Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C et al (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36:1221–1228CrossRefPubMed

42.

Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ (2004) Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190:641-649

43.

Schmitt-Hoffmann AH, Roos B, Heep M, Weidekamm E, Beglinger C. Pharmacokinetics of BAL4815, a new azole antifungal, after administration of single ascending oral doses of its pro-drug BAL8557. In: 43rd ICAAC Abstracts, American Society for Microbiology, September 2003, p 30, A-1568

44.

Schranz JA, Krause D, Goldstein BP, Henkel T (2003) Efficacy of Anidulafungin (ANID) for the treatment of candidemia. In: 43rd ICAAC abstracts, American Society for Microbiology, Sept 2003, p 448, M-971

45.

Steinbach WJ, Benjamin DK, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Jafri HS, Walsh TJ (2003) Invasive aspergillosis (IA) caused by Aspergillus terreus: multicenter retrospective analysis of 87 cases. In: 43rd ICAAC Abstracts, American Society for Microbiology, September 2003, p 475, M-1753

46.

Stute N, Kratochwille A, Zabelina T, Fehse N, Hassenpflug W, Panse J, Woltschke C, Ayuketang F, Schieder H, Renges H, von Hinüber R, Kabisch H, Zander AR, Kroge N (2003) Caspofungin is highly effective as secondary prophylaxis in allogeneic stem cell transplantation in patients with prior systemic or invasive fungal infections (abstract 3636). In: Proceedings 45th ASH 2003

47.

Troke PF, Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Fätkenheuer G, Schuler U, Thiel E, Dodell B, Lutsar I (2003) Voriconazole (VRC) therapy (Rx) in 86 patients (pts) with CNS aspergillosis (CNSA): a retrospective analysis. In: 43rd ICAAC Abstracts, American Society for Microbiology, September 2003, p 476, M-1755

48.

Ullmann A, Van Burik JA, McSweeney P, Ratanatharathorn V, Raymond J, de Morais VL, McGuirk J, Lau W, Facklam D, Koblinger S, Reusch M, Marr K, Patterson TF, Denning DW (2003) An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children (abstract). In: 13th ECCMID 10–13 May 2003

49.

Walsh TJ, Finberg RW, Arndt C et al (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764–771

50.

Walsh TJ, Roden M, Nelson L, Knudsen T, Venzon D, Segal B, Barrett J, Childs R (2002) Invasive fungal infections complicating non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT). In: Proceedings 42nd ICAAC, San Diego, 27–30 September 2002, M-1233

51.

Walsh TJ, Pappas P, Winston DJ et al (2002) Voriconazole versus liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients: a randomized, international, multicenter trial. N Engl J Med 340:764–771

52.

Walsh TJ, Patterson T, Langston A, van Burik J, Louie A, Herbrecht R, Hadley S, Perfect J, Hsu C, Gogate J, Hardalo C, Patino H, Pedicone L, Corcoran G, Raad I (2003) Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an externally controlled blinded trial (abstract 682). In: Proceedings 45th ASH 2003

53.

Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci R, Sable C, De Pauw B (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in persistent febrile neutropenic patients. N Engl J Med 351:1391–1402

54.

Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Leitz G, Territo MC (2003) Long-term antifungal prophylaxis in allogeneic bone marrow transplant patients: a multicenter, randomized trial of intravenous/oral itraconazole versus intravenous/oral fluconazole. Ann Intern Med 138:705–713

55.

Winston DJ, Emmanouilides C, Bartoni K, Schiller GJ, Paquette R, Territo MC (2003) Elimination of Aspergillus as a significant pathogen in an allogeneic hematopoietic stem cell transplant program after introduction of routine long-term itraconazole prophylaxis (abstract 685). In: Proceedings 45th ASH 2003

56.

Yadav SP, Chen S, Halliday C, Shaw PJ (2003) Serial Aspergillus PCR assays for the early diagnosis of invasive aspergillosis in children with leukemia or undergoing stem cell transplantation (abstract 3621). In: Proceedings 45th ASH 2003

57.

Rosen GP, Nielsen K, Pediatrics TM (2003) Fungal infections in pediatric bone marrow transplant recipients and non-transplant oncology patients (abstract 5535). In: Proceedings 45th ASH 2003

Titel: Recent developments in the management of invasive fungal infections in patients with hematological malignancies
verfasst von: Meinolf Karthaus
Oliver A. Cornely
Publikationsdatum: 01.04.2005
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 4/2005
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-004-0986-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2005

Treatment results of tonsillar lymphoma: a 10-year experience

Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine

Long-term results of dose density therapy in patients with aggressive lymphoma

Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis

Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information